Radiotherapy-Induced Oral Mucositis Treatment Market Projected to Surpass USD 1,626.0 Million by 2034 at a 3.8% of CAGR , Driven by Rising Cancer Cases and Increased Radiotherapy Use

Radiotherapy Induced Oral Mucositis Treatment Market

The global radiotherapy-induced oral mucositis treatment market is poised for significant growth, with an estimated market size of USD 1,119.8 million in 2024. This demand is primarily driven by the rising incidence of cancer and the corresponding increase in radiotherapy treatments, which often lead to oral mucositis as a prevalent side effect. As the number of individuals undergoing radiotherapy continues to rise, so does the need for effective treatments to manage and mitigate the symptoms of oral mucositis.

Forecasted to expand at a CAGR of 3.8% from 2024 through 2034, the market for radiotherapy-induced oral mucositis treatments is expected to reach a valuation of over USD 1,626.0 million by the end of this period. Pharmaceutical companies and medical device manufacturers are actively investing in research and development to introduce innovative solutions, including novel drugs, specialized oral rinses, and topical treatments aimed at preventing or reducing the severity of oral mucositis among cancer patients undergoing radiotherapy.

Adoption Analysis of the Radiotherapy Induced Oral Mucositis Treatment

• With the increasing use of telemedicine and remote monitoring technologies, healthcare providers can remotely monitor cancer patients undergoing radiotherapy and provide timely interventions for oral mucositis symptoms, improving patient outcomes and satisfaction.
• Recognizing the importance of nutrition in managing oral mucositis, companies are developing comprehensive nutritional support programs tailored to the unique dietary needs of cancer patients undergoing radiotherapy.
• Companies are establishing patient support groups and online communities to provide a platform for cancer patients undergoing radiotherapy to share their experiences, seek advice, and access resources for managing oral mucositis.

Competition Outlook of the Radiotherapy Induced Oral Mucositis Treatment Industry

The competition in the radiotherapy induced oral mucositis treatment industry is characterized by a mix of established pharmaceutical companies, emerging biotech firms, and specialized healthcare providers. Established players such as Pfizer, EpicentRx, Amgen, and Merck dominate with their extensive portfolios and global presence, leveraging their brand reputation and research capabilities to maintain market leadership.

However, the industry also sees the emergence of innovative startups and niche players focusing on developing targeted therapies and supportive care solutions for oral mucositis.

These challengers often differentiate themselves by offering novel treatment approaches, such as gene therapies or biologics, tailored to specific patient populations. Moreover, partnerships and collaborations between industry incumbents and academia drive innovation and accelerate the development of new treatment modalities.

In addition to pharmaceutical companies, medical device manufacturers play a crucial role in the industry by providing supportive care products and oral mucositis management devices. Companies like 3M Healthcare and Sage Products offer a range of oral care solutions designed to alleviate mucositis symptoms and improve patient comfort during radiotherapy treatment. This diversity in offerings further intensifies competition and fosters innovation within the market.

Recent Developments in the Radiotherapy Induced Oral Mucositis Treatment Industry:

• Galera Therapeutics submitted a New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care radiotherapy. However, the company received a Complete Response Letter (CRL) from the FDA, indicating that the NDA cannot be approved in its current form.
• EpicentRx is developing RRx-001, a novel immunotherapy that can sensitize tumors to radiotherapy and chemotherapy. The FDA has granted RRx-001 Orphan Drug Designation to prevent oral mucositis in patients with HNC.
• Pfizer has recently launched Zirabev, a biosimilar of bevacizumab, in the USA to treat various solid tumors. Zirabev has been shown to reduce the severity of oral mucositis in patients receiving radiotherapy for HNC in a randomized trial.
• Merck & Co. has also collaborated with Eisai to develop and commercialize eribulin, a microtubule inhibitor that can treat various types of cancer. Eribulin has been shown to reduce the incidence and severity of oral mucositis in patients with breast cancer receiving radiotherapy in a Phase 2 trial.

A Full Report Overview

Key Companies in the Market

• Galera Therapeutics
• OraVerse
• EpicentRx
• Biocon
• Oncodesign
• Cellectis
• Pfizer
• Amgen
• Merck & Co.

Key Segments

By Drug Class:

• Antibiotics
• Antifungal
• Anti-Inflammatory
• Anti-Neoplastic

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By End User:

• Hospitals
• Oncology Centres
• Research Institutes
• Dental Clinics

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube